Loading...

NRXP NRX PHARMACEUTICALS INC US FDA Inspections 8-K Filing

NRX

NRXP

NRX PHARMACEUTICALS INC

(NRXP)

2025 8-K

Accountant Change

Acquisition Details

Strategic Acquisition

FDA Approval Update

Acquisition Announcement

Funding Announcement

Stock Offering Details

FDA Designation Update

Pre-Market Approval

Financial Statements

Asset Acquisitions

Earnings Announcement

Stock Purchase Agreement

Capital Structure Update

Board Appointment

Board Resignation

Management Change

Financial Update

Acquisition Intent

Management Changes

Financial Results

Financing Agreement

Nasdaq Compliance Notice

Termination of Agreement

Appointment of Director

Financial Results and Debt ...

Default Notice and Clinical...

Public Offering

Increase in Offering Price

Financial Results Announcement

Reverse Stock Split

Stock Split Approved

Public Offering

Public Offering

Amendment to Convertible Pr...

Agreement Amendment and War...

Annual Meeting Approval

Adjournment of Annual Meeti...

Amendment to Include KPMG D...

Dismissal of Independent Re...

Earnings Reports

Appointment of Interim CFO ...

Securities Purchase Agreeme...

Private Placement

Investment Agreement

Amendment to Convertible Pr...

Securities Purchase Agreement

Agreement with Alvogen for ...

Delisting Notice

Financial Results Announcement

Securities Purchase Agreement

Stock Issuance Approval

Adjournment of Special Meeting

Resignation of Officer

FDA Meeting Minutes

Adjourned Special Meeting

External Links:

On September 24, 2025, NRX Pharmaceuticals, Inc. announced that the FDA granted a Suitability Petition for its single-patient ketamine product, KETAFREE™, allowing it to re-file its Abbreviated New Drug Application for the product. This development aims to replace the use of toxic preservatives in current ketamine sales.

AI Assistant

NRX PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.